Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc.
| REGENERON PHARMACEUTICALS, INC. |
| MYLAN PHARMACEUTICALS INC., BIOCON BIOLOGICS INC. and AMGEN USA, INC. |
| 24-1405 |
| January 30, 2024 |
| U.S. Court of Appeals, Federal Circuit |
| Patent Infringement (Fed. Qst.) |
Docket Report
RSS Track this Docket
This docket was last retrieved on January 30, 2024. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 2 Note to File: The following cases are consolidated: 24-1402 Lead with 24-1405 Cross-Appeal. The parties must file all documents in the lead appeal only. [980279] [24-1402, 24-1405] [JSP] [Entered: 01/30/2024 10:37 AM] |
| Filing 1 Appeal docketed. Received: 01/29/2024. [980275] Entry of Appearance is due on 02/13/2024. Certificate of Interest is due on 02/13/2024. Docketing Statement is due on 02/13/2024. Appellant's brief is due on 04/01/2024. [JSP] [Entered: 01/30/2024 10:27 AM] |
Access additional case information on PACER
Access the Case Summary and Docket Report to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
